tiprankstipranks
Trending News
More News >
Celularity (CELU)
NASDAQ:CELU
US Market

Celularity (CELU) Price & Analysis

Compare
190 Followers

CELU Stock Chart & Stats


Financials

Ownership Overview

35.62%2.57%3.62%56.06%
35.62% Insiders
3.62% Other Institutional Investors
56.06% Public Companies and
Individual Investors

CELU FAQ

What was Celularity’s price range in the past 12 months?
Celularity lowest stock price was $1.00 and its highest was $5.22 in the past 12 months.
    What is Celularity’s market cap?
    Celularity’s market cap is $48.14M.
      When is Celularity’s upcoming earnings report date?
      Celularity’s upcoming earnings report date is May 19, 2025 which is 25 days ago.
        How were Celularity’s earnings last quarter?
        Currently, no data Available
        Is Celularity overvalued?
        According to Wall Street analysts Celularity’s price is currently Overvalued. Get more investment ideas with TipRanks Premium
          Does Celularity pay dividends?
          Celularity does not currently pay dividends.
          What is Celularity’s EPS estimate?
          Celularity’s EPS estimate for its next earnings report is not yet available.
          How many shares outstanding does Celularity have?
          Celularity has 23,949,228 shares outstanding.
            What happened to Celularity’s price movement after its last earnings report?
            Currently, no data Available
            Which hedge fund is a major shareholder of Celularity?
            Currently, no hedge funds are holding shares in CELU

            Company Description

            Celularity

            Celularity Inc., a clinical-stage biotechnology company, develops off-the-shelf placental-derived allogeneic cell therapies for the treatment of cancer, immune, and infectious diseases. It operates through three segments: Cell Therapy, Degenerative Disease, and BioBanking. The company's lead therapeutic programs include CYCART-19, a placental-derived CAR-T therapy, which is in Phase I clinical trial for the treatment of B-cell malignancies; CYNK-001, placental-derived unmodified natural killer (NK) cell that is in Phase I clinical trial to treat acute myeloid leukemia, as well as in Phase I/IIa clinical trial for the treatment of glioblastoma multiforme and COVID-19; CYNK-101, an allogeneic genetically modified NK cell, which is in Phase I clinical trial to treat HER2+ gastric and gastroesophageal cancers; APPL-001, a placenta-derived mesenchymal-like adherent stromal cell that is in a pre-clinical stage for the treatment of Crohn's disease; and PDA-002, a placenta-derived mesenchymal-like adherent stromal cell, which is in pre-clinical stage for the treatment of facioscapulohumeral muscular dystrophy. It also sells and licenses products that are used in surgical and wound care markets, such as Biovance and Interfyl; collects stem cells from umbilical cords and placentas; and provides cells storage under the LifebankUSA brand. The company was incorporated in 2016 and is headquartered in Florham Park, New Jersey.
            Similar Stocks
            Company
            Price & Change
            Follow
            Lantern Pharma
            Generation Bio
            Repare Therapeutics
            Shattuck Labs
            FibroBiologics, Inc.
            Popular Stocks
            What am I Missing?
            Make informed decisions based on Top Analysts' activity
            Know what industry insiders are buying
            Get actionable alerts from top Wall Street Analysts
            Find out before anyone else which stock is going to shoot up
            Get powerful stock screeners & detailed portfolio analysis